Analyst Price Target is $61.14
▲ +99.49% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Celldex Therapeutics in the last 3 months. The average price target is $61.14, with a high forecast of $90.00 and a low forecast of $37.00. The average price target represents a 99.49% upside from the last price of $30.65.
Current Consensus is
Moderate Buy
The current consensus among 8 polled investment analysts is to moderate buy stock in Celldex Therapeutics. This rating has held steady since August 2023, when it changed from a Buy consensus rating.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More